Co-activation of Platelets by Prolactin or Leptin - Pathophysiological Findings and Clinical Implications

Abstract

Platelet activation is involved in the pathogenesis of atherosclerosis and venous thromboembolism, and might therefore be a possible link between the two entities. Prolactin and leptin have recently been recognized as potent co-activators of ADP-dependent platelet aggregation or P-selectin expression, and are therefore suspected as additional risk factors for both arterial and venous thrombosis. There are clinical situations that have a known association with higher prolactin or leptin levels (pregnancy, obesity or anti-psychotic therapy) and increased risk of thromboembolic events. We compared the impact of both hormones on platelet activation in vitro and in vivo, indicating that prolactin has a stronger effect on platelet activation as leptin in vitro and in vivo. We have also demonstrated that prolactin levels are increased in so called idiopathic thrombosis, and that conversely, patients with prolactinoma have an increased frequency of thrombosis during the hyperprolactinemic state, in a retrospective analysis. Moreover, we have demonstrated increased prolactin values in stroke and myocardial infarction. Prospective studies have yet to be performed to give this theory its final confirmation. The involvement of hormonal factors in platelet aggregation and venous or arterial thrombosis may have important clinical implications such as for risk stratification of patients with venous and arterial thrombosis or new therapeutic options such as decreasing pro-coagulant hormone levels in certain risk situations.

Prolactin - Leptin - Platelets - Venous thrombosis - Atherosclerosis

References

• 1 Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing A W, Prins M H, Girolami A. An association between atherosclerosis and venous thrombosis.  N Engl J Med.. 2003;  348 1435-1441
• 2 Foley P W, Irvine C D, Standen G R. et al . Activated protein C resistance, factor V Leiden and peripheral vascular disease.  Cardiovasc Surg. 1997;  5 157-160
• 3 Gaustadnes M, Rudiger N, Moller J, Rasmussen K, Bjerregaard Larsen T, Ingerslev J. Thrombophilic predisposition in stroke and venous thromboembolism in Danish patients.  Blood Coagul Fibrinolysis. 1999;  10 251-259
• 4 Marder V J, Matei D E. Hereditary and acquired thrombophilic syndromes. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN (eds) Hemostasis and thrombosis: basic principles & clinical practice. 4th ed. Philadelphia; Lippincott Williams & Wilkins 2000 (Foley PW, 1997): 1243-1276
• 5 Libby P, Simon D I. Thrombosis and atherosclerosis. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN (eds) Hemostasis and thrombosis: basic principles & clinical practice. 4th ed. Philadelphia; Lippincott Williams & Wilkins 2000: 743-752
• 6 Libby P. Multiple mechanisms of thrombosis complicating atherosclerotic plaques.  Clin Cardiol. 2000;  23 (Suppl 6) VI-3
• 7 Sueishi K, Ichikawa K, Kato K, Nakagawa K, Chen Y X. Atherosclerosis: coagulation and fibrinolysis.  Semin Thromb Hemost. 1998;  24 255-260
• 8 Holvoet P, Collen D. Thrombosis and atherosclerosis.  Curr Opin Lipidol. 1997;  8 320-328
• 9 FitzGerald G A, Tigges J, Barry P, Lawson J A. Markers of platelet activation and oxidant stress in atherothrombotic disease.  Thromb Haemost. 1997;  78 280-284
• 10 Drouet L, Mazoyer E, Bal dit Sollier C, Hainaud P, Ripoll L. Participation des mécanismes de la thrombose et de l’hémostase aux étapes initiales de l’athérosclérose.  Arch Mal Coeur Vaiss. 1998;  91 41-51
• 11 Koenig W, Rothenbacher D, Hoffmeister A, Griesshammer M, Brenner H. Plasma fibrin D-dimer levels and risk of stable coronary artery disease: results of a large case-control study.  Arterioscler Thromb Vasc Biol. 2001;  21 1701-1705
• 12 Ruggeri Z M. Platelets in atherothrombosis.  Nat Med. 2002;  8 1227-1234
• 13 Celi A, Lorenzet R, Furie B, Furie B C. Platelet-leukocyte-endothelial cell interaction on the blood vessel wall.  Semin Hematol. 1997;  34 327-335
• 14 Merten M, Thiagarajan P. P-selectin expression on platelets determines size and stability of platelet aggregates.  Circulation. 2000;  102 1931-1936
• 15  . Pulmonary Embolism Prevention trial Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial.  Lancet. 2000;  355 1295-1302
• 16 Collins R, Baigent C, Sandercock P, Peto R. Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials.  Antiplatelet Trialists’ Collaboration. BMJ. 1994;  309 1215-1217
• 17  . Collaborative overview of randomised trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists’ Collaboration.  BMJ. 1994;  308 235-246
• 18 Toglia M R, Weg J G. Venous thromboembolism during pregnancy.  N Engl J Med. 1996;  335 108-114
• 19 Greer I A. Thrombosis in pregnancy: maternal and fetal issues.  Lancet. 1999;  353 1158-1165
• 20 Rosendaal F R. Risk factors for venous thrombotic disease.  Thromb Haemost. 1999;  82 610-619
• 21 Dahlback B. Blood coagulation.  Lancet. 2000;  355 1627-1632
• 22 Dardenne M, de Moraes M, Kelly P A, Gagnerault M C. Prolactin receptor expression in human hematopoietic tissues analyzed by flow cytofluorometry.  Endocrinology. 1994;  134 2018-2114
• 23 Corash L. Measurement of platelet activation by fluorescence-activated flow cytometry.  Blood Cells. 1990;  16 97-106
• 24 Wallaschofski H, Donne M, Eigenthaler M, Hentschel B, Faber R, Stepan H, Koksch M, Lohmann T. PRL as a novel potent cofactor for platelet aggregation.  J Clin Endocrinol Metab. 2001;  86 5912-5919
• 25 Zornberg G I, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thrombembolism: a case-control study.  Lancet. 1999;  356 1219-1223
• 26 Wallaschofski H, Eigenthaler M, Kiefer M, Manfred D, Hentschel B, Gertz H J, Lohmann T. Hyperprolactinemia in patients on antipsychotic drugs causes ADP stimulated platelet activation that might explain the increased risk for venous thromboembolism.  In press
• 27 Wallaschofski H, Kobsar A, Siegemund A, Sokolova O, Hentschel B, Tuschy U, Lohmann T, Eigenthaler M. Prolactin Receptor Signaling during Platelet Activation.  M Horm Metab Res.. 2003;  35 228-235
• 28 Nakata M, Yada T, Soejima N, Maruyama I. Leptin promotes aggregation of human platelets via the long form of its receptor.  Diabetes. 1999;  48 426-429
• 29 Konstantinidis S, Schäfer K, Koschnick S, Loskutoff D J. Leptin-dependent platelet aggregation and arterial thrombosis suggest a mechanism for atherothrombotic disease in obesity.  J Clin Invest. 2001;  108 1533-1540
• 30 Maruyama I, Nakata M, Yamaji K. Effect of leptin in platelet and endothelial cells. Obesity and arterial thrombosis.  Ann N Y Acad Sci. 2000;  902 315-319
• 31 Printen K J, Miller E V, Mason E E, Barnes R W. Venous thromboembolism in the morbidly obese.  Surg Gynecol Obstet. 1978;  147 63-64
• 32 Konstantinides S, Schafer K, Loskutoff D J. The prothrombotic effects of leptin possible implications for the risk of cardiovascular disease in obesity.  Ann N Y Acad Sci Dec. 2001;  947 134-141; discussion 141 - 142
• 33 Ozata M, Avcu F, Durmus O, Yilmaz I, Ozdemir I C, Yalcin A. Leptin does not play a major role in platelet aggregation in obesity and leptin deficiency.  Obesity Research. 2001;  9 627-630
• 34 Bodary P F, Westrick R J, Wickenheiser K J, Shen Y, Eitzman D T. Effect of leptin on arterial thrombosis following vascular injury in mice.  JAMA. 2002;  287 1706-1709
• 35 Pirisi A. Leptin linked to blood clots in obesity.  Lancet. 2002;  359 1215
• 36 Wallaschofski H, Kobsar A, Sokolova O, Stepan H, Faber R, Siegemund A, Eigenthaler M, Lohmann T. Differences in platelet activation by prolactin and leptin.  Submitted
• 37 Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels.  Clin Endocrinol (Oxf). 1998;  48 547-553
• 38 Considine R V, Sinha M K, Heiman M L, Kriaciunas A, Stephens T W, Nyce M R, Ohanessian J P, Marco C C, McKee L J, Bauer T R, Caro T R. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl.  J Med. 1996;  334 292-295
• 39 Maffei M. et al . Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects.  Nat Med. 1995;  1 1155-1161
• 40 Friedman J M, Halaas J L. Leptin and the regulation of body weight in mammals.  Nature. 1998;  395 763-770
• 41 Boyar R M, Finkelstein J W, Kapen S, Hellman L. Twenty-four hour prolactin (PRL) secretory patterns during pregnancy.  J Clin Endocrinol Metab. 1975;  40 1117-1120
• 42 Sagawa N, Yura S, Itoh H, Mise H, Kakui K, Korita D, Takemura M, Nuamah M A, Ogawa Y, Masuzaki H, Nakao K, Fujii S. Role of leptin in pregnancy, a review.  Placenta. 2002;  23 (Suppl A) S80-86
• 43 Wauters M, Considine R V, Van Gaal L F. Human leptin: from an adipocyte hormone to an endocrine mediator.  Eur J Endocrinol. 2000;  143 293-311
• 44 Wieck A, Haddad P M. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review.  Br J Psychiatry. 2003;  182 199-204
• 45 Herran A, Garcia-Unzueta M T, Amado J A, de La Maza M T, Alvarez C, Vazquez-Barquero J L. Effects of long-term treatment with antipsychotics on serum leptin levels.  Br J Psychiatry. 2001;  179 59-62
• 46 Ross R. Atherosclerosis - an inflammatory disease.  N Engl J Med. 1999;  340 115-126
• 47 Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis.  J Leukoc Biol. 2000;  68 437-446
• 48 Walker S E, Yu-Lee L-Y. Overview: prolactin and autoimmunity.  Lupus. 2001;  10 669
• 49 Goffin V, Binart N, Touraine P, Kelly P A. Prolactin: The new biology of an old hormone.  Annu Rev Physiol. 2002;  64 47-67
• 50 Soderberg S, Ahren B, Stegmayr B, Johnson O, Wiklund P G, Weinehall L, Hallmans G, Olsson T. Leptin is a risk marker for first-ever hemorrhagic stroke in a population-based cohort.  Stroke. 1999;  30 328-337